Withania somnifera inhibits NF-κB and AP-1 transcription factors in human peripheral blood and synovial fluid mononuclear cells

Phytotherapy Research

Volumn 21, Issue 10, 2007, Pages 905-913

  Singh, Divya ^a   Aggarwal, Amita ^a   Maurya, Rakesh ^b   Naik, Sita ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antiinflammatory agents; I B; Immunomodulation; Natural products; Nitric oxide; Proinflammatory cytokines; Rheumatoid arthritis

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; WITHAFERIN A; WITHANIA SOMNIFERA EXTRACT;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MACROPHAGE; MONONUCLEAR CELL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; WESTERN BLOTTING; WITHANIA SOMNIFERA;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; ERGOSTEROL; HUMANS; I-KAPPA B PROTEINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; NF-KAPPA B; NITRIC OXIDE; PHOSPHORYLATION; PLANT EXTRACTS; RNA, MESSENGER; SYNOVIAL FLUID; TRANSCRIPTION FACTOR AP-1; WITHANIA; WITHANOLIDES;

WITHANIA SOMNIFERA;

EID: 35348907831     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2180     Document Type: Article

References (28)

1. Andallu B, Radhika B. 2000. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera) root. Indian J Exp Biol 38: 607-609.
2. Archana R, Namasivayan A. 1999. Antistressor effect of Withania somnifera. J Ethnopharmacol 64: 91-93.
3. Begum VH, Sadique J. 1988. Long-term effect of herbal drug Withania somnifera on adjuvant induced arthritis in rats. Indian J Exp Biol 26: 877-882.
4. Bhattacharya SK, Satyan KS, Ghosal S. 1997. Antioxidant activity of glycowithanolides from Withania somnifera. Indian J Exp Biol 35: 236-239.
5. Boyum A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by centrifugation, and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89.
6. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41: 2196-2204.
7. Choudhary MI, Yousuf S, Nawaz SA, Rahman A. 2004. Cholinesterase inhibiting withanolides from Withania somnifera. Chem Pharm Bull 52: 1358-1361.
8. Davis L, Kuttan G. 2000. Immunomodulatory activity of Withania somnifera. J Ethnopharmacol 71: 193-200.
9. Dhuley JN. 1997. Effect of some Indian herbs on macrophage functions in ochratoxin A treated mice. J Ethnopharmacol 58: 15-20.
10. Dhuley JN. 1998. Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 60: 173-178.
11. Dinarello CA. 1996. Biological basis for interleukin-1 in disease. Blood 87: 2095-2147.
12. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
13. Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Ann Rev Immunol 16: 225-260.
14. Goldblatt F, Isenberg DA. 2005. New therapies for rheumatoid arthritis. Clin Exp Immunol 140: 195-204.
15. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. 2006. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther 6: 1434-1445.
16. Kaileh M, Vanden Berghe W, Heyerick A et al. 2006. Withaferin A strongly elicits IKKbeta hyperphosphorylation, concomitant with potent inhibition of its kinase activity. J Biol Chem 282: 4253-4264.
17. Karin M, Liu Z, Zandi E. 1997. AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246.
18. Leyon PV, Kuttan G. 2004. Effect of Withania somnifera on B16F-10 melanoma induced metastasis in mice. Phytother Res 18: 118-122.
19. Mishra LC, Singh BB, Daganais S. 2000. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): A review. Altern Med Rev 5: 334-346.
20. Mosmann T. 1982. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 5.
21. Pandey R, Maurya R, Singh G, Sathiamoorthy B, Naik S. 2005. Immunosuppressive properties of flavonoids isolated from Boerhaavia diffusa Linn. Int Immunopharmacol 5: 541-553.
22. Shahnan JC, Clair WS. 2002. Tumor necrosis factor-α blockade: A novel therapy for rheumatoid arthritis. Clin Immunol 103: 231-242.
23. Shaila D, Kulkarni SM, Itikala RL, Itikala S. 2006. Determination of Withaferin A in two Withania species by RP-HPLC method. Indian J Pharm Sci 68: 253-256.
24. Subbaraju GV, Vanisree M, Rao CV et al. 2006. Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of Withania somnifera. J Nat Prod 69: 1790-1792.
25. Vassalli P. 1992. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452.
26. Xie Q, Kashiwabara Y, Nathan C. 1994. Role of transcription factor NF-κB/ Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-4708.
27. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C, Komatsu K. 2002. Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities. Chem Pharm Bull 50: 760-765.
28. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B. 1996. Studies on the immunomodulatory effects of Ashwagandha. J Ethnopharmacol 50: 69-76.